Jazz wins FDA approval for Ziihera regimens in first-line HER2+ gastroesophageal cancer, triggering USD 250 million Zymeworks milestone
ZYME•Zymeworks to receive milestone payment
Zymeworks will receive a USD 250 million milestone from Jazz, remaining eligible for up to USD 1.3 billion more.
FDA approves two first-line Ziihera regimens
FDA cleared two first-line Ziihera (zanidatamab-hrii) regimens for unresectable or metastatic HER2+ gastroesophageal adenocarcinoma.
Jazz can market Ziihera with Tevimbra (tislelizumab) and chemotherapy for all HER2+ patients, regardless of PD-L1 status.
